Gen. Pharmac. Vol. 20, No. 6, pp. I-X, 1989 Pergamon Press plc. Printed in Great Britain

NEW PATENTS

This Section contains abstracts and, where appropriate, illustrations of recently issued United States patents and published patent applications filed from over 30 countries under the Patent Cooperation Treaty. This information was obtained from recent additions to the Pergamon PATSEARCH ® online database in accordance with interest profiles developed by the Editors. Further information about Pergamon PATSEARCH ® can be obtained from Pergamon Orbit InfoLine Inc., 8000 Westpark Drive, McLean, Virginia 22102 U.S.A.

Copies of complete patents announced in this Section are available from Pergamon Orbit InfoLine Inc. for $8 per copy. Payment with order is required. Orders outside North America add $2 for air postage. Order by patent number for Pergamon Orbit InfoLine only.

4826677 4826688

PHARMACEUTICAL MATERIAL FOR THE TREATMENT OF

PSORIASIS

Josef Mueller, Hans-Ulrich Petereit, Lindenfels, Federal Republic Of Germany assigned to Rohm Pharma GmbH

The invention relates to pharmaceutical materials for local and non-irritating therapy for psoriasis, containing antipsoriatic ingredients. The pharmaceutical material is a liquid prepara- tion of film-forming polymers and antipsoriatic ingredients, with which the psoriasis affected skin area can be covered and treated in situ with a medicated film or foil formed at the treatment site. Dithranol and/or glucocorticoid in com- bination with keratolytically acting urea are pre- ferred for use as antipsoriatic ingredients.

4826~0

PHARMACEUTICAL COMPOSITION CONTAINING

THYMUS EXTRACT FRACTIONS

Karl-Heinz Jaeger, Luzern, Switzerland as- signed to Dr Kurt Mulli N a c h f G m b H & Co K G

A pharmaceutical composition is described, which contains a fraction consisting of low molecular proteins and/or oligo peptides, and a yellow fraction containing riboflavine, which is associated with organ specific oligo peptides, which fractions are obtainable by fractionation of thymus extract. This composition has a significant immuno stimulating activity, and can be used for the treatment of immuno deficiency diseases, as for example, for T-cell-deficiencies.

CONTROLLED ABSORPTION PHARMACEUTICAL

FORMULATION

Donald E Panoz, Edward J Geoghegan, Tucker- stown, Bermuda assigned to 501 Elan Corpora- tion PLC

A controlled absorption quinidine formulation for oral administration comprises a pellet having a core of quinidine or a pharmaceutically ac- ceptable salt thereof in association with an or- ganic acid and optionally other excipients, and an outer membrane which permits release of quinidine in an aqueous medium at a controlled rate which is substantially pH independent. The pellet has a dissolution rate in vitro, which when measured in a Basket Assembly according to U.S. Pharmacopoeia XXI at 37 degrees C. and 75 r.p.m, is not more than 15% after one hour of measurement. Not more than 50% of the total quinidine is release after a total of 4 hours of measurement, not more than 80% is released af- ter a total of 8 hours of measurement and not less than 90% release is achieved after a total of 24 hours.

482~26

METHYLATED CHITOSANS AND THEIR USE FOR THE

PREPARATION OF PHARMACEUTICAL

COMPOSITIONS

Franco Conti, Milan, Italy assigned to Establis- sement Texcontor